Reports

Sale

Hospital Acquired Disease Testing Market

Global Hospital Acquired Disease Testing Market Size, Share: By Indication: UTI (Urinary Tract Infection), SSI, Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus); Regional Analysis; Market Dynamics: SWOT Analysis, Porter’s Five Forces Analysis; Competitive Landscape; 2024-2032

Global Hospital Acquired Disease Testing Market Outlook 

The global hospital acquired disease testing market attained a value of USD 1609.43 million in 2023. The market is further anticipated to reach USD 6312.63 million by 2032 while registering a CAGR of 16.4% over the forecast period of 2024-2032.

 

On the basis of the indication, the urinary tract infection segment is estimated to be the largest indication segment. The segment growth is primarily attributed to the rising incidences of immune suppression accompanied by urologic abnormality due to the consumption of unhealthy food, alcohol, and smoking.

Regionally, North America is anticipated to dominate the market in 2020, owing to the increasing reimbursement policies and favourable government initiatives towards hospital acquired (nosocomial) infections.

 

Hospital Acquired Disease Testing Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Properties and Applications 

A hospital acquired infection (HAI) or diseases or nosocomial infection is an infection which is acquired from the hospital or the clinical surrounding including nursing homes, and rehabilitation centres, among others. The incubation period of the nosocomial infection generally varies between 48 hours to 4 days. The prime reason behind the cause of HAI is the lack of proper hygiene in the hospital or clinical environment by the internal staff. Also, other factors that can be attributed to the growth of HAI include below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the commonly occurring nosocomial infections include pneumonia, urinary tract infections (UTI), and primary bloodstream infections. 

On the basis of indication, the market is segmented into:

  • UTI (Urinary Tract Infection)
  • SSI (Surgical Site Infection)
  • Pneumonia
  • Bloodstream Infections
  • MRSA (Methicillin-Resistant Staphylococcus Aureus)
  • Others

The EMR report looks into the regional markets of hospital acquired disease testing like Europe, the Asia Pacific, North America, Latin America, and the Middle East and Africa.

 

Market Analysis 

With the increasing global population, rapid urbanisation, and modernisation of healthcare infrastructure, there has been a significant increase in the number of health care facilities. This has led to the rising incidence of HAIs, which, in turn, is propelling the demand for hospital acquired disease tests. The rising adoption of advanced technologies for preventing, diagnosing, and monitoring HAIs, such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridisation, is further expected to augment the market growth.

Moreover, the growing awareness of HAIs among patients and stringent government regulations to penalize hospitals with a high incidence of HAIs are some of the other factors that are strengthening the growth of the market. Increasing research and development activities for developing new techniques, coupled with various mergers and acquisitions and strategic partnerships by various manufacturers, are expected to create potential revenue opportunities for players operating in the market over the forecast period.

 

Competitive Landscape 

The report presents a detailed analysis of the following key players in the global hospital acquired disease testing market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Siemens Healthcare GmbH
  • Others

The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter's Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Indication
  • Region
Breakup by Indication
  • UTI (Urinary Tract Infection)
  • SSI (Surgical Site Infection)
  • Pneumonia
  • Bloodstream Infections
  • MRSA (Methicillin-Resistant Staphylococcus Aureus)
  • Others
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Siemens Healthcare GmbH
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Opportunities and Challenges in the Market
8    Global Hospital Acquired Disease Testing Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Hospital Acquired Disease Testing Historical Market (2018-2023) 
    8.3    Global Hospital Acquired Disease Testing Market Forecast (2024-2032)
    8.4    Global Hospital Acquired Disease Testing Market by Indication
        8.4.1    UTI (Urinary Tract Infection)  
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2018-2023)
            8.4.1.3    Forecast Trend (2024-2032)
        8.4.2    SSI (Surgical Site Infection) 
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2018-2023)
            8.4.2.3    Forecast Trend (2024-2032)
        8.4.3    Pneumonia 
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2018-2023)
            8.4.3.3    Forecast Trend (2024-2032)
        8.4.4    Bloodstream Infections 
            8.4.4.1    Market Share
            8.4.4.2    Historical Trend (2018-2023)
            8.4.4.3    Forecast Trend (2024-2032)
        8.4.5    MRSA (Methicillin-Resistant Staphylococcus Aureus)  
            8.4.5.1    Market Share
            8.4.5.2    Historical Trend (2018-2023)
            8.4.5.3    Forecast Trend (2024-2032)
        8.4.6    Others 
    8.5    Global Hospital Acquired Disease Testing Market by Region
        8.5.1    North America
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2018-2023)
            8.5.1.3    Forecast Trend (2024-2032)
        8.5.2    Europe
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2018-2023)
            8.5.2.3    Forecast Trend (2024-2032)
        8.5.3    Asia Pacific
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2018-2023)
            8.5.3.3    Forecast Trend (2024-2032)
        8.5.4    Latin America
            8.5.4.1    Market Share
            8.5.4.2    Historical Trend (2018-2023)
            8.5.4.3    Forecast Trend (2024-2032)
        8.5.5    Middle East and Africa
            8.5.5.1    Market Share
            8.5.5.2    Historical Trend (2018-2023)
            8.5.5.3    Forecast Trend (2024-2032)
9    North America Hospital Acquired Disease Testing Market Analysis
    9.1    United States of America
        9.1.1    Market Share
        9.1.2    Historical Trend (2018-2023)
        9.1.3    Forecast Trend (2024-2032)
    9.2    Canada
        9.2.1    Market Share
        9.2.2    Historical Trend (2018-2023)
        9.2.3    Forecast Trend (2024-2032)
10    Europe Hospital Acquired Disease Testing Market Analysis
    10.1    United Kingdom
        10.1.1    Market Share
        10.1.2    Historical Trend (2018-2023)
        10.1.3    Forecast Trend (2024-2032)
    10.2    Germany
        10.2.1    Market Share
        10.2.2    Historical Trend (2018-2023)
        10.2.3    Forecast Trend (2024-2032)
    10.3    France
        10.3.1    Market Share
        10.3.2    Historical Trend (2018-2023)
        10.3.3    Forecast Trend (2024-2032)
    10.4    Italy
        10.4.1    Market Share
        10.4.2    Historical Trend (2018-2023)
        10.4.3    Forecast Trend (2024-2032)
    10.5    Others
11    Asia Pacific Hospital Acquired Disease Testing Market Analysis
    11.1    China
        11.1.1    Market Share
        11.1.2    Historical Trend (2018-2023)
        11.1.3    Forecast Trend (2024-2032)
    11.2    Japan
        11.2.1    Market Share
        11.2.2    Historical Trend (2018-2023)
        11.2.3    Forecast Trend (2024-2032)
    11.3    India
        11.3.1    Market Share
        11.3.2    Historical Trend (2018-2023)
        11.3.3    Forecast Trend (2024-2032)
    11.4    ASEAN
        11.4.1    Market Share
        11.4.2    Historical Trend (2018-2023)
        11.4.3    Forecast Trend (2024-2032)
    11.5    Australia
        11.5.1    Market Share
        11.5.2    Historical Trend (2018-2023)
        11.5.3    Forecast Trend (2024-2032)
    11.6    Others
12    Latin America Hospital Acquired Disease Testing Market Analysis
    12.1    Brazil
        12.1.1    Market Share
        12.1.2    Historical Trend (2018-2023)
        12.1.3    Forecast Trend (2024-2032)
    12.2    Argentina
        12.2.1    Market Share
        12.2.2    Historical Trend (2018-2023)
        12.2.3    Forecast Trend (2024-2032)
    12.3    Mexico
        12.3.1    Market Share
        12.3.2    Historical Trend (2018-2023)
        12.3.3    Forecast Trend (2024-2032)
    12.4    Others
13    Middle East  and Africa Hospital Acquired Disease Testing Market Analysis
    13.1    Saudi Arabia
        13.1.1    Market Share
        13.1.2    Historical Trend (2018-2023)
        13.1.3    Forecast Trend (2024-2032)
    13.2    United Arab Emirates
        13.2.1    Market Share
        13.2.2    Historical Trend (2018-2023)
        13.2.3    Forecast Trend (2024-2032)
    13.3    Nigeria
        13.3.1    Market Share
        13.3.2    Historical Trend (2018-2023)
        13.3.3    Forecast Trend (2024-2032)
    13.4    South Africa
        13.4.1    Market Share
        13.4.2    Historical Trend (2018-2023)
        13.4.3    Forecast Trend (2024-2032)
    13.5    Others
14    Market Dynamics
    14.1    SWOT Analysis
        14.1.1    Strengths
        14.1.2    Weaknesses
        14.1.3    Opportunities
        14.1.4    Threats
    14.2    Porter’s Five Forces Analysis
        14.2.1    Supplier’s Power
        14.2.2    Buyer’s Power
        14.2.3    Threat of New Entrants
        14.2.4    Degree of Rivalry
        14.2.5    Threat of Substitutes
    14.3    Key Indicators for Demand
    14.4    Key Indicators for Price
15    Value Chain Analysis
16    Competitive Landscape

    16.1    Market Structure
    16.2    Company Profiles
        16.2.1    Abbott Laboratories
            16.2.1.1    Company Overview
            16.2.1.2    Product Portfolio
            16.2.1.3    Demographic Reach and Achievements
            16.2.1.4    Certifications
        16.2.2    Becton, Dickinson and Company
            16.2.2.1    Company Overview
            16.2.2.2    Product Portfolio
            16.2.2.3    Demographic Reach and Achievements
            16.2.2.4    Certifications
        16.2.3    F. Hoffmann-La Roche Ltd.
            16.2.3.1    Company Overview
            16.2.3.2    Product Portfolio
            16.2.3.3    Demographic Reach and Achievements
            16.2.3.4    Certifications
        16.2.4    Hologic, Inc.
            16.2.4.1    Company Overview
            16.2.4.2    Product Portfolio
            16.2.4.3    Demographic Reach and Achievements
            16.2.4.4    Certifications
        16.2.5    Siemens Healthcare GmbH
            16.2.5.1    Company Overview
            16.2.5.2    Product Portfolio
            16.2.5.3    Demographic Reach and Achievements
            16.2.5.4    Certifications
        16.2.6    Others
17    Key Trends and Developments in the Market


List of Key Figures and Tables

1.    Global Hospital Acquired Disease Testing Market: Key Industry Highlights, 2018 and 2032
2.    Global Hospital Acquired Disease Testing Historical Market: Breakup by Indication (USD Million), 2018-2023
3.    Global Hospital Acquired Disease Testing Market Forecast: Breakup by Indication (USD Million), 2024-2032
4.    Global Hospital Acquired Disease Testing Historical Market: Breakup by Region (USD Million), 2018-2023
5.    Global Hospital Acquired Disease Testing Market Forecast: Breakup by Region (USD Million), 2024-2032
6.    North America Hospital Acquired Disease Testing Historical Market: Breakup by Country (USD Million), 2018-2023
7.    North America Hospital Acquired Disease Testing Market Forecast: Breakup by Country (USD Million), 2024-2032
8.    Europe Hospital Acquired Disease Testing Historical Market: Breakup by Country (USD Million), 2018-2023
9.    Europe Hospital Acquired Disease Testing Market Forecast: Breakup by Country (USD Million), 2024-2032
10.    Asia Pacific Hospital Acquired Disease Testing Historical Market: Breakup by Country (USD Million), 2018-2023
11.    Asia Pacific Hospital Acquired Disease Testing Market Forecast: Breakup by Country (USD Million), 2024-2032
12.    Latin America Hospital Acquired Disease Testing Historical Market: Breakup by Country (USD Million), 2018-2023
13.    Latin America Hospital Acquired Disease Testing Market Forecast: Breakup by Country (USD Million), 2024-2032
14.    Middle East and Africa Hospital Acquired Disease Testing Historical Market: Breakup by Country (USD Million), 2018-2023
15.    Middle East and Africa Hospital Acquired Disease Testing Market Forecast: Breakup by Country (USD Million), 2024-2032
16.    Global Hospital Acquired Disease Testing Market Structure

Key Questions Answered in the Report

In 2023, the global hospital acquired disease testing market attained a value of nearly USD 1609.43 million.

In the forecast period of 2024-2032, the market is expected to grow at a CAGR of 16.4%.

By 2032, the market is expected to attain a value of USD 6312.63 million.

The major drivers of the market include the increasing incidences of immune suppression, the introduction of favourable government initiatives aimed at increasing reimbursement policies towards hospital acquired diseases, and growing global population.

The modernisation of healthcare, the rising adoption of advanced technologies for preventing, diagnosing, and treating hospital acquired diseases, growing awareness regarding hospital acquired diseases among patients, and increasing research activities to develop advanced diagnostic technologies are the key trends guiding the market.

The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The significant indication segments considered in the market report include UTI (urinary tract infection), SSI (surgical site infection), pneumonia, bloodstream infections, and MRSA (methicillin-resistant staphylococcus aureus), among others.

The major players in the market are Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Hologic, Inc., and Siemens Healthcare GmbH, among others.

Analyst Review

The global hospital acquired disease testing market attained a value of USD 1609.43 million in 2023, driven by the modernisation of the healthcare infrastructure. Aided by technological advancements, the market is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 16.4%. The market is projected to reach USD 6312.63 million by 2032. 

EMR's meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on indication, the market can be segmented into UTI (urinary tract infection), SSI (surgical site infection), pneumonia, bloodstream infections, and MRSA (methicillin-resistant staphylococcus aureus), among others, with UTI (urinary tract infection) accounting for the largest market share. The major regional markets for hospital acquired disease are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share of the market. The key players in the above market include Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Hologic, Inc., and Siemens Healthcare GmbH, among others.

EMR's research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.  Global Hospital Acquired Disease Testing Market

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER